Pharmacopsychiatry 2020; 53(02): 96
DOI: 10.1055/s-0039-3403044
P6 Neuropharmacology
Georg Thieme Verlag KG Stuttgart · New York

Include me if you can!: Reasons for low enrollment of pediatric patients in a psychopharmacological trial

A Haege
1   Zentralinstitut für Seelische Gesundheit Mannheim, Germany
,
K Mechler
1   Zentralinstitut für Seelische Gesundheit Mannheim, Germany
,
L Niemeyer
1   Zentralinstitut für Seelische Gesundheit Mannheim, Germany
,
J Buitelaar
1   Zentralinstitut für Seelische Gesundheit Mannheim, Germany
,
S Durston
1   Zentralinstitut für Seelische Gesundheit Mannheim, Germany
,
BR Gooskens
1   Zentralinstitut für Seelische Gesundheit Mannheim, Germany
,
B Oranje
1   Zentralinstitut für Seelische Gesundheit Mannheim, Germany
,
T Banaschewski
1   Zentralinstitut für Seelische Gesundheit Mannheim, Germany
,
RW Dittmann
1   Zentralinstitut für Seelische Gesundheit Mannheim, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
24 February 2020 (online)

 

Introduction Low recruitment in clinical trials is a common and costly problem which undermines medical research. This study aimed to investigate the challenges faced in recruiting children and adolescents with obsessive-compulsive disorder (OCD) and autism spectrum disorder (ASD) for a randomized, double-blind, placebo-controlled clinical trial and to analyze reasons for non-participation. The trial was part of the EU FP7 project TACTICS (Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes (www.tactics-project.eu, FP7/2007-2013, grant agreement number 278948, EudraCT Number: 2014-003080-38).

Methods Demographic data on pre-screening patients were collected systematically, including documented reasons for non-participation. Findings were grouped according to content, and descriptive statistical analyses of the data were performed.

Results In total, n = 173 patients were pre-screened for potential participation in the clinical trial. Of these, only five (2.9%) were eventually enrolled. The main reasons for non-inclusion were: failure to meet all inclusion criteria/meeting one or more of the exclusion criteria (n = 73; 42.2% of pre-screened patients); no interest in the trial or trials in general (n = 40; 23.1%); not wanting changes to current therapy/medication (n = 14; 8.1%).

Conclusion The findings from this study add valuable information to the existing knowledge on reasons for low clinical trial recruitment rates in pediatric psychiatric populations. Low enrollment and high exclusion rates raise the question of whether such selective study populations are representative of clinical patient cohorts. Consequently, the generalizability of the results of such trials may be limited. The present findings will be useful in the development of improved recruitment strategies and may guide future research in establishing the measurement of representativeness to ensure enhanced external validity in psychopharmacological clinical trials in pediatric populations. Furthermore, researchers are encouraged to collect and publish detailed findings on recruitment difficulties and reasons for non-participation in clinical trials, in order to develop respective new tools and concepts based on sound data.